CD82 controls CpG-dependent TLR9 signaling

被引:22
|
作者
Khan, Nida S. [1 ,2 ,5 ]
Lukason, Daniel P. [1 ,4 ]
Feliu, Marianela [1 ]
Ward, Rebecca A. [1 ]
Lord, Allison K. [1 ]
Reedy, Jennifer L. [1 ,5 ]
Ramirez-Ortiz, Zaida G. [5 ,6 ,7 ]
Tam, Jenny M. [1 ]
Kasperkovitz, Pia V. [9 ]
Negoro, Paige E. [1 ]
Vyas, Tammy D. [1 ]
Xu, Shuying [1 ]
Brinkmann, Melanie M. [10 ,11 ]
Acharaya, Mridu [12 ,13 ]
Artavanis-Tsakonas, Katerina [14 ]
Frickel, Eva-Maria [15 ]
Becker, Christine E. [8 ]
Dagher, Zeina [1 ]
Kim, You-Me [16 ]
Latz, Eicke [3 ,17 ,18 ]
Ploegh, Hidde L. [19 ]
Mansour, Michael K. [1 ,5 ]
Miranti, Cindy K. [20 ,21 ]
Levitz, Stuart M. [3 ]
Vyas, Jatin M. [1 ,5 ]
机构
[1] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA
[2] Univ Massachusetts Med Sch, Biomed Engn & Biotechnol, Boston, MA USA
[3] Univ Massachusetts Med Sch, Dept Med, Boston, MA USA
[4] Univ Massachusetts, Biomed Engn & Biotechnol, Lowell, MA USA
[5] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA
[6] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02115 USA
[7] Harvard Med Sch, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA
[8] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02115 USA
[9] F Hoffmann La Roche Innovat Ctr Basel, Basel, Switzerland
[10] Helmholtz Ctr Infect Res, Viral Immune Modulat Res Grp, Braunschweig, Germany
[11] Tech Univ Carolo Wilhelmina Braunschweig, Inst Genet, Braunschweig, Germany
[12] Benaroya Res Inst, Seattle, WA USA
[13] Seattle Childrens Res Inst, Ctr Immun & Immunotherapy, Seattle, WA USA
[14] Univ Cambridge, Dept Pathol, Cambridge, England
[15] Francis Crick Inst, Host Toxoplasma Interact Lab, London, England
[16] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon, South Korea
[17] Univ Bonn, Univ Hosp Bonn, Inst Innate Immun, Bonn, Germany
[18] German Ctr Neurodegenerat Dis DZNE, Bonn, Germany
[19] Boston Childrens Hosp, Boston, MA USA
[20] Van Andel Res Inst, Lab Integrin Signaling & Tumorigenesis, Grand Rapids, MI USA
[21] Univ Arizona, Canc Ctr, Dept Cellular & Mol Med, Tucson, AZ USA
来源
FASEB JOURNAL | 2019年 / 33卷 / 11期
基金
英国医学研究理事会; 英国惠康基金; 美国国家卫生研究院;
关键词
tetraspanins; TLRs; myddosome; macrophages; RECEPTOR; 9; PROTEOLYTIC CLEAVAGE; ANTIGEN PRESENTATION; INNATE IMMUNITY; DECTIN-1; ACTIVATION; PROTEIN; TRAFFICKING; INDUCTION; PATHWAY;
D O I
10.1096/fj.201901547R
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The tetraspanin CD82 is a potent suppressor of tumor metastasis and regulates several processes including signal transduction, cell adhesion, motility, and aggregation. However, the mechanisms by which CD82 participates in innate immunity are unknown. We report that CD82 is a key regulator of TLR9 trafficking and signaling. TLR9 recognizes unmethylated cytosine-phosphate-guanine (CpG) motifs present in viral, bacterial, and fungal DNA. We demonstrate that TLR9 and CD82 associate in macrophages, which occurs in the endoplasmic reticulum (ER) and post-ER. Moreover, CD82 is essential for TLR9-dependent myddosome formation in response to CpG stimulation. Finally, CD82 modulates TLR9-dependent NF-kappa B nuclear translocation, which is critical for inflammatory cytokine production. To our knowledge, this is the first time a tetraspanin has been implicated as a key regulator of TLR signaling. Collectively, our study demonstrates that CD82 is a specific regulator of TLR9 signaling, which may be critical in cancer immunotherapy approaches and coordinating the innate immune response to pathogens.
引用
收藏
页码:12500 / 12514
页数:15
相关论文
共 50 条
  • [1] Differential signaling by CpG DNA in DCs and B cells: not just TLR9
    Verthelyi, D
    Zeuner, RA
    TRENDS IN IMMUNOLOGY, 2003, 24 (10) : 519 - 522
  • [2] Activation of rabbit TLR9 by different CpG-ODN optimized for mouse and human TLR9
    Liu, Jin
    Xu, Congfeng
    Liu, Yi-Ling
    Matsuo, Hanako
    Hsieh, Rebecca Pe-Feng
    Lo, Jeng-Fan
    Tseng, Ping-Hui
    Yuan, Chiun-Jye
    Luo, Yunping
    Xiang, Rong
    Chuang, Tsung-Hsien
    COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES, 2012, 35 (05) : 443 - 451
  • [3] Aacetaminophen hepatotoxicity is dependent on TLR9 and can be reduced by a TLR9 antagonist
    Mahmood, Shamail
    Watanabe, Azuma
    Sohail, Muhammad A.
    Flavell, Richard A.
    Mehal, Wajahat Z.
    GASTROENTEROLOGY, 2008, 134 (04) : A752 - A752
  • [4] Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists
    Vollmer, Joerg
    Krieg, Arthur M.
    ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (03) : 195 - 204
  • [5] Distribution of TLR9 and uptake of CpG in human neutrophils
    Hedrick, TL
    Smith, RL
    King, CS
    McElearney, ST
    Saalwachter, AR
    Rudy, CK
    Du, KP
    Pruett, TL
    Sawyer, RG
    FASEB JOURNAL, 2005, 19 (04): : A373 - A373
  • [6] CpG Oligodeoxynucleotides as TLR9 AgonistsTherapeutic Applications in Cancer
    Yanal M. Murad
    Timothy M. Clay
    BioDrugs, 2009, 23 : 361 - 375
  • [7] Bacterial CpG-DNA licenses TLR9
    Bauer, S
    Wagner, H
    TOLL-LIKE RECEPTOR FAMILY MEMBERS AND THEIR LIGANDS, 2002, 270 : 145 - 154
  • [8] TLR9的特性及其介导的TLR9/CpG-DNA免疫信号通路
    桑丽敏
    唐立
    中国微生态学杂志, 2010, 22 (12) : 1143 - 1146+1149
  • [9] CpG Ofigodeoxynudeofides as TLR9 Agonists Therapeutic Applications in Cancer
    Murad, Yanal M.
    Clay, Timothy M.
    BIODRUGS, 2009, 23 (06) : 361 - 375
  • [10] The TLR9 agonist CpG ODN attenuates cardiac hypertrophy
    Yang, L.
    Jiao, J.
    Zhang, J.
    Li, J.
    Tang, X.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (06) : 1011 - 1011